Application of bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody for the in vivo analysis of proliferative characteristics of human leukemia cells in bone marrows

Oncology. 1991;48(4):285-9. doi: 10.1159/000226944.

Abstract

To investigate the proliferative characteristics of human bone marrow leukemic cells in vivo, we developed a new method using bromodeoxyuridine (BrdU) and its monoclonal antibody. Thirty minutes after a bolus BrdU infusion, a lst bone marrow aspiration (BMP) was performed to calculate the BrdU labeling index (BrdU-LI). Then, a 150-min continuous infusion of BrdU was started. Immediately after the infusion, a 2nd BMP was done to analyze the increasing rate of the BrdU-LI for 3 h. Each smear was stained by an immunohistochemical method. The BrdU-LI, the duration of S phase (Ts) and the cell cycle time (Tc) of leukemic cells from 13 previously untreated patients with acute leukemias were estimated. A mean value of 7.2% for BrdU-LI was obtained. Furthermore, mean values of 9.7 h and 152.5 h for Ts and Tc respectively were calculated. This method may prove to be useful in the in vivo cell cycle analysis of leukemias and other malignancies.

MeSH terms

  • Antibodies, Monoclonal*
  • Bone Marrow / pathology*
  • Bromodeoxyuridine* / immunology
  • Cell Cycle
  • Cell Division
  • Female
  • Humans
  • Kinetics
  • Leukemia / pathology*
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Promyelocytic, Acute / pathology
  • Male
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Staining and Labeling

Substances

  • Antibodies, Monoclonal
  • Bromodeoxyuridine